Evotec's Nine-Month Beat Meets a Muted Fourth Quarter — and a New Science Chief

Evotec delivered preliminary figures for the first nine months of 2026 that came in ahead of market expectations, yet the German biotech's full-year guidance stayed exactly where it was. That combination — a backward-looking beat paired with an unchanged outlook — sits at the heart of the cautious stance Deutsche Bank Research maintained on the stock today.

The broker kept its rating at "Hold" and left its price target at EUR 3.50. Analyst Fynn Scherzler acknowledged that the headline numbers were stronger than anticipated, but flagged the prospects for the closing quarter as a negative surprise. The result is a split verdict: what Evotec has already booked looks solid, while the months still to come look considerably less certain.

What the preliminary numbers show

For the nine months through September, Evotec reported provisional revenue of roughly EUR 465.0 million and an adjusted EBITDA of about EUR -42.8 million. According to the company, both figures topped what the market had been looking for.

The annual forecast, however, was reaffirmed without change. Beating expectations for the year to date therefore did not translate into upgraded targets for the full twelve months — a distinction that separates a positive earnings surprise from a genuinely improved outlook.

Investors will get the complete picture on November 5, 2026, when Evotec is scheduled to publish its third-quarter and nine-month results. That date offers the next official opportunity to weigh the preliminary figures and the guidance side by side.

A leadership change running on a different clock

Alongside the debate over the business trajectory, Evotec announced a boardroom shift. Dr. Joanna Holbrook will become Chief Scientific Officer and a member of the management board effective November 1, 2026, tasked with steering the company's global scientific strategy.

Her résumé is substantial: more than 25 years in science and R&D, most recently at Novo Nordisk, where she headed the cardiovascular, renal and liver disease areas as well as in-vitro discovery platforms. At Evotec, her remit extends beyond any single therapeutic field — the stated goal is to sharpen the differentiation of the company's research and development offering.

That appointment opens a longer-term angle but says nothing yet about operational momentum. Holbrook has not yet taken up her post, so no near-term earnings impact can be read into the announcement. Anyone treating the hire as an operational turning point would be getting ahead of verifiable progress.

Two houses, two views

Not every analyst shares Deutsche Bank's restraint. H.C. Wainwright today reiterated its buy recommendation with a price target of USD 4.00 — an expectation, not evidence of an improvement already achieved.

With the stock trading at EUR 2.56, the market is left to weigh two competing narratives. The bull case rests on the preliminary results having cleared expectations; if the underlying business proves more resilient than the subdued quarterly outlook suggests, that alone could support a recovery, no personnel decision required. The bear case centers on the gap between those surprising figures and the dampened expectations for the final quarter. Should the closing stretch indeed come in weak, the better nine-month numbers may be read as a limited victory, and an unchanged annual forecast would hardly justify a more optimistic view.

The risk for investors, then, is not that the Holbrook appointment is meaningless. It lies in linking strategic potential too quickly to short-term business dynamics. Deutsche Bank's neutral rating illustrates that strong quarterly data points and caution about the outlook can comfortably coexist.

What to watch from here

Until the stronger headline figures are matched by a more convincing perspective on the fourth quarter, a sustained recovery remains a story that needs telling. Should signs of a steadier operating performance accumulate, the new scientific leadership could complement that trend strategically. If the skeptical read on year-end business is confirmed, the appointment alone is unlikely to offer much counterweight.

November 1 marks the start of Holbrook's responsibility, not the success of her strategy. After that, the question for shareholders becomes how concretely Evotec fleshes out the promised differentiation of its R&D portfolio. Near term, operational resilience is what counts; over the longer haul, the scientific realignment has to prove itself. Only when both pieces line up would a more confident assessment rest on firmer ground.